Orchard To Work On Reversing English Funding Refusal For Libmeldy Gene Therapy
Reimbursement Discussions Are Also Ongoing In Other Major European Markets
Health technology assessment body NICE has welcomed further discussion between Orchard Therapeutics and the National Health Service to resolve its concerns over the company’s one-time gene therapy for the neurodegenerative disorder, metachromatic leukodystrophy, in children.
